R&D | Cutting-edge science and innovative research

News

AstraZeneca cuts ribbon on new R&D facility in Massachusetts

AstraZeneca's has opened a new R&D centre in the biotech hotspot of Cambridge, Massachusetts, the centrepiece of a $1bn investment in the state.

News

Vaxcyte's pneumococcal jab exceeds expectations

Shares in Vaxcyte have rocketed on phase 3 trial data for its pneumococcal vaccine VAX-31 that suggests it could take on rivals from Pfizer and MSD.

News

Nobel Prize in Physiology or Medicine winners 2026

Nobel Prize in Medicine awarded to optogenetics trio

The 2026 Nobel Prize in Physiology or Medicine has been awarded jointly to optogenetics pioneers Karl Deisseroth, Peter Hegemann, and Georg Nagel.

R&D

Digital representation of sepsis bacteria attacking heart

The hidden pandemic within the pandemic: How COVID-19 impact...

Why sepsis readiness – equipment, supply chains, surveillance, and public awareness – needs to be treated as core pandemic infrastructure.

News

CSL joins forces with Alentis on claudin candidate

CSL has licensed rights to a potentially first-in-class anti-claudin-1 antibody developed by Alentis in a deal that could be worth up to $1.55bn.

News

Aldo Faisal and Tracking ethomic biomarkers.
Bodily movement sensors combined with new AI tool allow researchers to track movements and predict disease progression in movement disorders.

Aldo is pictured with Ms Luchen Li, Department of Computing who is wearing the sensor suit.

Dr Balasundaram Kadirvelu who leads on the project is pictured seated with Luchen in some of the images with the bodysuit.

Movie motion capture tech tested for disease tracking

Motion capture technology used to bring fantasy characters to life in movies like Avatar and The Lord of the Rings is being used alongside artificial intelligence (AI) to track diseases tha

News

ASCO-GI data sets up wider use of Ipsen's Onivyde

Ipsen and partner Servier hope to extend the uses of their pancreatic cancer therapy Onivyde into the first-line treatment setting, assisted by new phase 3 data reported at the ASCO-GI 2023

News

Jazz swings on ASCO-GI data for zanidatamab

Jazz Pharma's $325 million gamble on rights to Zymeworks' HER2-directed bispecific antibody zanidatamab was the largest in its history, and seems like a safer bet after a mid-stage readout

Debates & Insights

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Webinars

Sponsored

Synthetic control arms in clinical trials: Making it happen

Across the industry, pharma companies are turning to AI and real-world data to address many of the challenges of running clinical trials.

R&D

Sponsored

How synthetic control arms are changing clinical trials

Clinical trials are involved, expensive, and have been done largely the same way for decades but with today’s technology all that can change. With drawn-out timelines and billions

News

AstraZeneca cuts ribbon on new R&D facility in Massachusetts

AstraZeneca's has opened a new R&D centre in the biotech hotspot of Cambridge, Massachusetts, the centrepiece of a $1bn investment in the state.

News

Vaxcyte's pneumococcal jab exceeds expectations

Shares in Vaxcyte have rocketed on phase 3 trial data for its pneumococcal vaccine VAX-31 that suggests it could take on rivals from Pfizer and MSD.

Press Releases

Media Partner

PHARMAP 2027 Addresses the Future of Pharmaceutical Manufact...

Senior pharma professionals gather in Berlin on 19-20 April for the Pharmaceutical Manufacturing and Packaging Congress (PHARMAP) 2027

Press Releases

Partner Content

The Evolution Summit Announces September 2026 Program for Cl...

Marcus Evans announces The Evolution Summit, taking place September 28-29, 2026 at Park Hyatt Aviara Resort, Golf Club & Spa, San Diego, CA.

Views & Analysis

R&D

The hidden pandemic within the pandemic: How COVID-19 impact...

Why sepsis readiness – equipment, supply chains, surveillance, and public awareness – needs to be treated as core pandemic infrastructure.

R&D

Silhouette of a head with white brain under magnifying glass inside outline, against yellow background

Alzheimer’s: Starting the impossible journey

September was Alzheimer’s Month, and with that in mind pharmaphorum spoke to leaders at two biotechs about latest developments in the field.

R&D

pharmaphorum podcast Episode 278, Shai Melcer, IIA

Bioconvergence & future human health, with Shai Melcer

Shai Melcer discusses bioconvergence, a multidisciplinary research and development approach that merges technologies.

Deep Dive

R&D

Cancer misinformation is a trust problem, not just an inform...

R&D

The GLP-1 Reckoning

R&D

The success of clinical trials hinges on a complex array of factors, many of which extend beyond traditional clinical care.

Podcasts

R&D

Bioconvergence & future human health, with Shai Melcer

Shai Melcer discusses bioconvergence, a multidisciplinary research and development approach that merges technologies.

R&D

pharmaphorum podcast Episode 272, Dr Harpreet Singh, Precision for Medicine

Understanding Operation Trialblazer, with Dr Harpreet Singh

Dr Harpreet Singh, CMO at Precision for Medicine, brings both an insider and outsider perspective to discussing Operation TRIALBLAZER.

R&D

A New Framework to Engineer Breakthrough Value for Medicines

A new white paper from Lumanity – ‘A New Framework to Engineer Breakthrough Value for Medicines: Value Inflection Points Across the Development Path’.